Results 11 to 20 of about 15,701 (194)

Empagliflozin protects the heart against ischemia/reperfusion-induced sudden cardiac death

Cardiovascular Diabetology, 2021
Background Empagliflozin is a selective sodium–glucose cotransporter 2 (SGLT2) inhibitor used to lower blood sugar in adults with type 2 diabetes. Empagliflozin also exerts cardioprotective effects independent from glucose control, but its benefits on ...
Zhaoyang Hu, Feng Ju, Lei Du, Geoffrey W. Abbott   +3 more
doaj   +1 more source

Empagliflozin Induces White Adipocyte Browning and Modulates Mitochondrial Dynamics in KK Cg-Ay/J Mice and Mouse Adipocytes

Frontiers in Physiology, 2021
Background: White adipose tissue (WAT) browning is a promising target for obesity prevention and treatment. Empagliflozin has emerged as an agent with weight-loss potential in clinical and in vivo studies, but the mechanisms underlying its effect are not
Linxin Xu, Linxin Xu, Chaofei Xu, Xiangyang Liu, Xiaoyu Li, Ting Li, Xiaochen Yu, Mei Xue, Jing Yang, Constantine E. Kosmas, Dimitrios Moris, Fabian Sanchis-Gomar, Naofumi Yoshida, Nathan A. Berger, Wilbert S. Aronow, Bei Sun, Liming Chen   +16 more
doaj   +1 more source

Empagliflozin attenuates cardiac microvascular ischemia/reperfusion injury through improving mitochondrial homeostasis

Cardiovascular Diabetology, 2022
Background Empagliflozin has been reported to protect endothelial cell function, regardless of diabetes status. However, the role of empagliflozin in microvascular protection during myocardial ischemia reperfusion injury (I/R) has not been fully ...
Rongjun Zou, Wanting Shi, Junxiong Qiu, Na Zhou, Na Du, Hao Zhou, Xinxin Chen, Li Ma   +7 more
doaj   +1 more source

Dapagliflozin versus empagliflozin in patients with chronic kidney disease

Frontiers in Pharmacology, 2023
Background and Aim: Dapagliflozin and empagliflozin have demonstrated favorable clinical outcomes among patients with chronic kidney disease (CKD). However, their comparative monetary value for improving outcomes in CKD patients is unestablished.
Hilmi Alnsasra, Hilmi Alnsasra, Gal Tsaban, Gal Tsaban, Adam Solomon, Fouad Khalil, Enis Aboalhasan, Abed N. Azab, Abed N. Azab, Joseph Azuri, Joseph Azuri, Ariel Hammerman, Ronen Arbel   +12 more
doaj   +1 more source

Empagliflozin protects against renal ischemia/reperfusion injury in mice

Scientific Reports, 2022
Renal ischemia/reperfusion (I/R) can induce acute kidney injury. Empagliflozin is a newly developed inhibitor of sodium-glucose cotransporter-2 (SGLT2) approved as an antidiabetic medication for patients with type 2 diabetes mellitus.
Qifeng Wang, Feng Ju, Jiaxue Li, Ting Liu, Yunxia Zuo, Geoffrey W. Abbott, Zhaoyang Hu   +6 more
doaj   +1 more source

Association between Empagliflozin Use and Electrocardiographic Changes

Clinics and Practice, 2022
Empagliflozin, a sodium-glucose transporter 2 inhibitor, has been shown to bind to late sodium channels in mice cardiomyocytes. We sought to investigate the electrocardiographic (ECG) features associated with empagliflozin use in patients with diabetes ...
Daniel Antwi-Amoabeng, Sunil Sathappan, Bryce D. Beutler, Mark B. Ulanja, Munadel Awad, Nageshwara Gullapalli, Phillip Duncan, T. David Gbadebo   +7 more
doaj   +1 more source

Investigating the Role of Empagliflozin in the Pathological Progress of Ischemia-Reperfusion Injury in Rat Kidneys: The Involvement of Nitric Oxide [PDF]

Advanced Pharmaceutical Bulletin
Purpose: Renal ischemia-reperfusion (RIR) is a pathological condition that can lead to severe outcomes due to damage to kidney structures. Additionally, oxidative stress is triggered by mitochondrial disruption during reperfusion, potentially resulting ...
Amin Hasanvand, Abdolreza Tajdar, Azita Zafar Mohtashami, Zahra Haghighatian, Elham Goodarzi, Peyman Amanolahi Baharvand, Babak Hadian   +6 more
doaj   +1 more source

Comparison of the effects of empagliflozin and glimepiride on endothelial function in patients with type 2 diabetes: A randomized controlled study.

PLoS ONE, 2022
Patients with type 2 diabetes who have cardiovascular disease and are receiving empagliflozin have a lower rate of primary composite cardiovascular outcomes.
Haruka Tamura, Yoshinobu Kondo, Kohei Ito, Masanori Hasebe, Shinobu Satoh, Yasuo Terauchi   +5 more
doaj   +1 more source

Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure

ESC Heart Failure, 2022
Aims In this prospective, placebo‐controlled, double‐blind, exploratory study, we examined early and more delayed effects of empagliflozin treatment on haemodynamic parameters (primary endpoint: cardiac output) and kidney function including parameters of
Kirsten Thiele, Matthias Rau, Niels‐Ulrik Korbinian Hartmann, Marcus Möller, Julia Möllmann, Joachim Jankowski, András P. Keszei, Michael Böhm, Jürgen Floege, Nikolaus Marx, Michael Lehrke   +10 more
doaj   +1 more source

Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 Signalling Pathways

Journal of Immunology Research, 2021
Background. Sodium-glucose cotransporter 2 (SGLT2) and dipeptidyl peptidase-4 (DPP-4) inhibitors are glucose-lowering drugs whose anti-inflammatory properties have recently become useful in tackling metabolic syndromes in chronic inflammatory diseases ...
Nami Lee, Yu Jung Heo, Sung-E Choi, Ja Young Jeon, Seung Jin Han, Dae Jung Kim, Yup Kang, Kwan Woo Lee, Hae Jin Kim   +8 more
doaj   +1 more source